Published in Vaccine on September 15, 2000
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin Vaccine Immunol (2010) 0.97
Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun (2003) 0.90
Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins. Clin Diagn Lab Immunol (2004) 0.78
Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol (2008) 0.76
Genome sequence of Yersinia pestis, the causative agent of plague. Nature (2001) 14.36
Occurrence of Clostridium perfringens beta2-toxin amongst animals, determined using genotyping and subtyping PCR assays. Epidemiol Infect (2000) 2.18
Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun (1996) 2.17
The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis. Infect Immun (2000) 2.10
Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun (1995) 2.04
A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine (1995) 2.03
Structure of the key toxin in gas gangrene. Nat Struct Biol (1998) 1.89
Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine (2001) 1.86
Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun (1997) 1.77
Lipoproteins of bacterial pathogens. Infect Immun (2010) 1.73
A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine (1997) 1.70
Efficacy of doxycycline and ciprofloxacin against experimental Yersinia pestis infection. J Antimicrob Chemother (1998) 1.60
An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol (1999) 1.57
Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis. Infect Immun (2006) 1.54
Cloning and nucleotide sequencing of the Clostridium perfringens epsilon-toxin gene and its expression in Escherichia coli. Infect Immun (1992) 1.52
A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect Immun (2002) 1.45
A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene. Vaccine (1993) 1.40
Application of high-density array-based signature-tagged mutagenesis to discover novel Yersinia virulence-associated genes. Infect Immun (2001) 1.39
Sequence of the gene for alkaline phosphatase from Escherichia coli JM83. Nucleic Acids Res (1986) 1.38
Preliminary analysis and annotation of the partial genome sequence of Francisella tularensis strain Schu 4. J Appl Microbiol (2001) 1.37
A single dose sub-unit vaccine protects against pneumonic plague. Vaccine (2000) 1.35
A Caenorhabditis elegans model of Yersinia infection: biofilm formation on a biotic surface. Microbiology (2003) 1.35
Sequence of the adenine methylase gene of the Streptococcus faecalis plasmid pAM beta 1. Nucleic Acids Res (1987) 1.33
The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol Med Microbiol (1999) 1.31
Rapid identification of flaviviruses based on conserved NS5 gene sequences. J Virol Methods (1993) 1.30
Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect Immun (1995) 1.29
Yersinia pestis pFra shows biovar-specific differences and recent common ancestry with a Salmonella enterica serovar Typhi plasmid. J Bacteriol (2001) 1.29
Sequencing of the Francisella tularensis strain Schu 4 genome reveals the shikimate and purine metabolic pathways, targets for the construction of a rationally attenuated auxotrophic vaccine. Microb Comp Genomics (2000) 1.25
Factors affecting the germination of spores of Bacillus anthracis. J Appl Bacteriol (1987) 1.23
Molecular genetic analysis of beta-toxin of Clostridium perfringens reveals sequence homology with alpha-toxin, gamma-toxin, and leukocidin of Staphylococcus aureus. Infect Immun (1993) 1.20
Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb Pathog (1997) 1.18
The pH 6 antigen of Yersinia pestis binds to beta1-linked galactosyl residues in glycosphingolipids. Infect Immun (1998) 1.15
In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp. Antimicrob Agents Chemother (1999) 1.15
Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine (1994) 1.14
The failure of different strains of Yersinia pestis to produce lipopolysaccharide O-antigen under different growth conditions is due to mutations in the O-antigen gene cluster. FEMS Microbiol Lett (2001) 1.13
Screening examination of the larynx and pharynx during upper gastrointestinal panendoscopy. Gastrointest Endosc (1982) 1.11
Mechanism of inhibition of protein kinase C by 14-3-3 isoforms. 14-3-3 isoforms do not have phospholipase A2 activity. Biochem J (1994) 1.08
Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol Med Microbiol (1998) 1.07
Thoughts of harming infants in depressed and nondepressed mothers. J Affect Disord (1999) 1.06
Simultaneous detection of microorganisms in soil suspension based on PCR amplification of bacterial 16S rRNA fragments. Biotechniques (1996) 1.06
Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS). Microb Pathog (2007) 1.05
Detection of spores of Bacillus anthracis using the polymerase chain reaction. J Infect Dis (1992) 1.05
Molecular variation between the alpha-toxins from the type strain (NCTC 8237) and clinical isolates of Clostridium perfringens associated with disease in man and animals. Microbiology (1996) 1.04
Antibody responses to Yersinia pestis F1-antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters. Vaccine (2000) 1.03
The purification and some properties of H-lysin from Aeromonas salmonicida. J Gen Microbiol (1985) 1.03
Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. J Antimicrob Chemother (2000) 1.02
Identification of residues critical for toxicity in Clostridium perfringens phospholipase C, the key toxin in gas gangrene. Eur J Biochem (2000) 1.02
Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine (1996) 1.02
An aroA mutant of Yersinia pestis is attenuated in guinea-pigs, but virulent in mice. Microbiology (1996) 1.02
The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J Antimicrob Chemother (1998) 1.02
Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol (2001) 1.01
Polysaccharides and virulence of Burkholderia pseudomallei. J Med Microbiol (2007) 1.00
Nucleotide sequence of the NS5 gene of Banzi virus: comparison with other flaviviruses. J Gen Virol (1995) 1.00
Production of a non-toxic site-directed mutant of Clostridium perfringens epsilon-toxin which induces protective immunity in mice. Microbiology (1998) 1.00
A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice. Vaccine (2006) 0.98
The construction of a reporter system and use for the investigation of Clostridium perfringens gene expression. FEMS Microbiol Lett (1995) 0.98
Characterization of the lipopolysaccharide of Yersinia pestis. Microb Pathog (2001) 0.97
Doxycycline or ciprofloxacin prophylaxis and therapy against experimental Yersinia pestis infection in mice. J Antimicrob Chemother (1996) 0.96
Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague. Microb Pathog (1999) 0.95
Epitope mapping of the alpha-toxin of Clostridium perfringens. Infect Immun (1991) 0.95
Investigation into the role of the serine protease HtrA in Yersinia pestis pathogenesis. FEMS Microbiol Lett (2000) 0.95
Characterisation of the calcium-binding C-terminal domain of Clostridium perfringens alpha-toxin. J Mol Biol (1999) 0.94
Comparison of the nucleotide sequence and development of a PCR test for the epsilon toxin gene of Clostridium perfringens type B and type D. FEMS Microbiol Lett (1992) 0.93
Expression of heterologous O-antigen in Yersinia pestis KIM does not affect virulence by the intravenous route. J Med Microbiol (2003) 0.93
Differences in the carboxy-terminal (Putative phospholipid binding) domains of Clostridium perfringens and Clostridium bifermentans phospholipases C influence the hemolytic and lethal properties of these enzymes. Infect Immun (1999) 0.92
Effect of different plasmids on colonization of mouse tissues by the aromatic amino acid dependent Salmonella typhimurium SL 3261. Microb Pathog (1994) 0.91
RelA regulates virulence and intracellular survival of Francisella novicida. Microbiology (2009) 0.91
An assessment of the in vitro toxicology of Clostridium perfringens type D epsilon-toxin in human and animal cells. Hum Exp Toxicol (2000) 0.90
Presymptomatic prediction of sepsis in intensive care unit patients. Clin Vaccine Immunol (2008) 0.90
cspB encodes a major cold shock protein in Clostridium botulinum ATCC 3502. Int J Food Microbiol (2011) 0.90
Salmonella Gallinarum field isolates from laying hens are related to the vaccine strain SG9R. Vaccine (2013) 0.89
The detection of insertion sequences within the human pathogen Burkholderia pseudomallei which have been identified previously in Burkholderia cepacia. FEMS Microbiol Lett (1998) 0.89
Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif (2000) 0.89
Clindamycin-associated hepatotoxicity. Am J Med (1974) 0.89
Laboratory diagnosis of plague. Br J Biomed Sci (1997) 0.89
Degradation of thyrotropin-releasing hormone and luteinising hormone-releasing hormone by enzymes of brain tissue. J Neurochem (1990) 0.88
Clostridium perfringens phospholipase C-induced platelet/leukocyte interactions impede neutrophil diapedesis. J Med Microbiol (2006) 0.88
Protection afforded by heat shock protein 60 from Francisella tularensis is due to copurified lipopolysaccharide. Infect Immun (2004) 0.88
Analysis of murine Snrpn and human SNRPN gene imprinting in transgenic mice. Mamm Genome (1999) 0.87
Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague. Vaccine (2006) 0.86
Role of caseinase from Aeromonas salmonicida in activation of hemolysin. Infect Immun (1985) 0.85
UDP-glucose deficiency causes hypersensitivity to the cytotoxic effect of Clostridium perfringens phospholipase C. J Biol Chem (1998) 0.85
Recombinant vaccinia viruses protect against Clostridium perfringens alpha-toxin. Viral Immunol (1999) 0.84
Identification of residues in the carboxy-terminal domain of Clostridium perfringens alpha-toxin (phospholipase C) which are required for its biological activities. Arch Biochem Biophys (2000) 0.84
Vaccines against dangerous pathogens. Br Med Bull (2002) 0.83
Transformation of Burkholderia pseudomallei by electroporation. Anal Biochem (1996) 0.83
Detection of surgical lesions of the small bowel by enteroclysis. Am J Surg (1984) 0.83
Tyrosine 331 and phenylalanine 334 in Clostridium perfringens alpha-toxin are essential for cytotoxic activity. FEBS Lett (2001) 0.82
Induction of emetic, pyrexic, and behavioral effects of Staphylococcus aureus enterotoxin B in the ferret. Infect Immun (2000) 0.82
Purification, crystallization and preliminary X-ray diffraction studies of alpha-toxin of Clostridium perfringens. J Mol Biol (1994) 0.81
Probing molecular interactions in intact antibody: antigen complexes, an electrospray time-of-flight mass spectrometry approach. Biophys J (2001) 0.81
Analysis of a cloned Francisella tularensis outer membrane protein gene and expression in attenuated Salmonella typhimurium. FEMS Microbiol Lett (1993) 0.81
Sequence of the Bacillus caldotenax and Bacillus stearothermophilus lctB genes. Nucleic Acids Res (1987) 0.80
Stabilisation of Salmonella vaccine vectors by the induction of trehalose biosynthesis. Vaccine (2000) 0.80
Proposed topology of the glucitol permeases of Escherichia coli and Clostridium acetobutylicum. Curr Microbiol (1996) 0.80
Idiopathic interstitial pulmonary fibrosis. An immune complex disease? Am Rev Respir Dis (1973) 0.79
Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity. Vaccine (2012) 0.78
Macromolecular organization of the Yersinia pestis capsular F1 antigen: insights from time-of-flight mass spectrometry. Protein Sci (2001) 0.78
Bacterial phospholipases. Trends Microbiol (1997) 0.78